Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis.

This research suggests that the optimal first-line treatment in the UK is adalimumab biosimilar. The optimal second-line and third-line treatments depend on the magnitude of confidential discounts applied to the biologic treatments.